The modern aspects of pharmacotherapy of chronic venous insufficiency (CVI) 
Chronic venous insufficiency (CVI) of the lower extremities is a syndrome characterized by disorders of the venous outflow on the macrohemodynamic level, it leads to disorganization of the regional microcirculation system [6, 16] . CVI is considered to be the most common peripheral vascular disease. The high level of morbidity of the working-age population reaching 40-50% by expert estimations allows to conclude that CVI is an important medical and social problem. Furthermore, if previously the disease was predominantly a problem of persons of the senior age group (over 50 years), at the present time the first signs of venous reflux are found in 10-15% of 12-13 years school children [5, 24] .
The main predisposing factors of CVI are: • hereditary or acquired valvular insufficiency of the veins; • decrease of the tone of the varicose vein wall; • high pressure due to the blood reflux from the deep venous system to the surface venous system [7, 21, 22] . CVI of the lower extremities is primarily characterized by stagnation or redistribution of the venous blood flow in the venous system. The mechanism of its development is associated with hypertension in the inferior vena cava forming as a result of the varicose transformation of the venous wall or its thrombus burden [6, 22] . Initial macrohemodynamic disorders lead to the serious changes at the tissue level. The result of this process is development of microcirculatory disorders in the form of trophic disorders.
Until recently, the sufficient attention has not been paid to pharmacotherapy of CVI in Ukraine. The cause for this situation is the absence of effective, available and safe drugs. The situation has radically changed in the last two decades when the improvement of pharmaceutical technologies has led to the appearance a new generation of phlebotropic drugs at the pharmaceutical market [4, 5, 7] .
Medications of the basic pharmacotherapy CVI are phlebotropic drugs (PHD) (synonyms are veno-active drugs, phleboprotector drugs, venotonic drugs). They are a heterogeneous group of biologically active substances obtained by processing of plant raw material or by chemical synthesis. The ability to increase the venous tone and reduce the venospecific symptoms and syndromes of CVI is a common feature of the pharmacodynamics of these drugs [1, 18] .
It should be noted that more than 20 PHD have been registered and are used in Ukraine. The main phlebotropic drugs and their daily doses are shown in Table 1 .
Flavonoids are the most studied among the basic venotonic drugs. Drugs based on Diosmin, which are especially widely used in the international phlebological practice, are prescribed more often than others [1, 2, 13]. Most experts call Micronized Purified Flavonoid Fraction (MPFF), which has the brand name "Detralex", the reference phleboprotector drug because of its multitargeted mechanism of action, ease of use, high bioavailability and safety [3, 12, 20] .
An important feature of micronized Diosmin is a rapid onset of the venotonic effect, the effect is shown already from the first hour after administration, and lasts during the day [1, 15] . This action is successfully complemented by improved rheological properties of the blood, reduction in blood viscosity [2, 3], stimulation of the drainage function of lymphatic vessels [11, 23] .
Most PHD increase the tone of peripheral veins and lymphatic vessels due to the effect on the norepinephrine-dependent mechanism, and also due to some specific effects of individual drugs [8] . Requirements for PHD are not limited only by increase of the venous wall tone. Modern veno-active drugs should have the ability to stimulate the lymphatic drainage and improve microcirculation [9, 15] . Basic clinical effects of different PHD are presented in Table 2 .
The main indication for the use of PHD is the symptoms associated with chronic venous insufficiency such as heavy legs, discomfort, itching, pain along the varicose veins, paresthesia, night cramps, and other venospecific complaints, chronic venous edema, and trophic skin disorders, including venous ulcers. The results of numerous clinical studies suggest that at early stages of the disease all PHD have a good therapeutic effect on subjective symptoms of CVI, but not the objective symptoms of CVI such as telangiectasia, varicose reticular and subcutaneous veins [10, 13] . At the same time in choosing the drug therapy at early stages of CVI the preference should be given to PHD with the efficacy and safety proven in randomized controlled clinical studies. Chronic venous edema is an absolute indication for PHD [14] . According to the meta-analysis data MPFF shows the most evident anti-edematous effect, which is the drug of first choice in chronic venous edma [15] .
Hydroxyethyl rutosides (Venoruton) and the extract of Ruscus aculeatus (Cyclo 3 fort) also reduce the chronic venous edema and can be the second line drugs. Efficiency of non-micronized (native) Diosmin in regard to the chronic venous edema is not significantly different from placebo. To assess the efficiency of other phlebotropic drugs in the chronic venous edema it is necessary to conduct numerous randomized clinical studies according to standardized protocols [11, 29] .
Phlebotropic drugs should be administered in adequate doses, which are recommended by drug manufacturers, as well as the standard therapeutic schemes and duration of treatment should be observed. The excess of the standard daily doses does not necessarily improve the clinical effect, but increases the frequency of unwanted side effects that can break the started course of pharmacotherapy. However, results of certain clinical research indicate that in some clinical situations Table 2 The therapeutic effects and mechanisms of action of phlebotropic drugs the increase in the dose of the phlebotropic drug can increase its therapeutic efficacy. In this connection, in situations when the benefit of the drug outweighs the potential risk, the dose of the phlebotropic drug can be increased after documentary evidence and obtaining of the informed consent of the patient [17] . Phlebotropic drugs can be prescribed as monotherapy or fixed combinations (multi-drug) since the simultaneous use of two or more drugs belonging to related chemical classes does not intensify the therapeutic effect, but increases the probability of undesirable side reactions.
PHD are relatively well tolerated by most patients even if taken them for long time. The undesirable dyspeptic disorders (stomach pain, diarrhea, vomiting, etc.) and vegetative disorders (insomnia, dizziness, etc.) are observed in no more than 5% of patients [23] . The typical undesirable side reactions of various PHD are presented in Table 3 .
Treatment should be given by courses, which duration depends on disease severity, and lasts 2-3 months, but not less than twice a year. The interval between courses should be used for physical therapy or SPA treatment. The continuous therapeutic scheme can be used in the case of refractory forms of CVI [7, 25] . MPFF has the highest safety profile in the long-term use (6-12 months) [1, 3, 19, 20] .
According to standard protocols adapted to each stage and form of CVI the randomized controlled clinical studies should be conducted for all new phlebotropic and phleboprotector drugs in order to assess their efficacy and safety [16, 25] . Formal bioequivalence of generic and original drugs can not guarantee the similar clinical effect and safety [1, 7, 20] . CONCLUSIONS In conclusion, it should be noted that the rational pharmacological therapy allows to perform effective pathogenetic and symptomatic treatment of various forms and complications of CVI. The promising development of this method is implemented in several directions. Among them the following ones should be distinguished:
-the search of new chemical substances which selectively block the synthesis of adhesion molecules, leukocyte activation factors and tissue metalloproteases;
-the study of drugs that stimulate and control the synthesis of the connective tissue; -optimization of delivery methods of pharmacological agents in the affected area with the help of nanotechnology.
The successful implementation of these programmes in the future will allow to speak about the possibility of the effective control of CVI. 
